Good progress in the projects towards important clinical events
SECOND QUARTER IN BRIEF
Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab
EVENTS AFTER THE END OF THE PERIOD
Active Biotech provided status update on the progress in its clinical naptumomab project- Active Biotech’s partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance, featuring combination with naptumomab as one approach
Financial summary
SEK M | Apr-Jun | Jan-Jun | Full-year | |||||
2021 | 2020 | 2021 | 2020 | 2020 | ||||
Net sales | - | - | - | 0.5 | 6.7 | |||
Operating profit/loss | -12.6 | -10.1 | -22.4 | -19.9 | -32.3 | |||
Profit/loss after tax | -12.6 | -9.8 | -22.4 | -19.9 | -32.2 | |||
Earnings per share (SEK) | -0.06 | -0.06 | -0.11 | -0.12 | -0.19 | |||
Cash and cash equivalents (at close of period) | 78.5 | 38.2 | 26.2 | |||||
For further information, please contact:
Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | (Corp. Reg. No. 556223-9227) Scheelevägen 22, 223 63 Lund Tel: +46 (0)46 19 20 00 |
The report is also available at www.activebiotech.com.
Attachment
Active Biotech Interim Report Jan-Jun 2021
Source:
2021 GlobeNewswire, Inc., source